CancerDrs

Liver Cancer clinical trials in California

76 actively recruiting liver cancer trials at 44 sites across California.

Data from ClinicalTrials.gov · last refreshed

Payments from drug makers to the doctors running these trials

For 3 of the trials on this page, the pharmaceutical company funding the trial also disclosed payments to the physicians leading it — public data from the federal CMS Open Payments database. Paying clinical-trial investigators for site work is expected and necessary for industry-funded trials; the scale and source are simply useful context when you're deciding whether to enroll.

Phase 3 Recruiting Academic/Other

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

This phase III trial compares the effect of immunotherapy (IO) with stereotactic body radiation therapy (SBRT) to IO alone in treating patients with liver cancer (hepatocellular cancer) that may have spread from where it first started to n…

Sponsor: NRG Oncology
NCT ID: NCT07166406
Sites in California:
  • Alta Bates Summit Medical Center-Herrick Campus — Berkeley, California
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park — Cameron Park, California
  • Palo Alto Medical Foundation-Fremont — Fremont, California
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • Palo Alto Medical Foundation-Camino Division — Mountain View, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…

Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in California:
  • Research Site — Palo Alto, California
  • Research Site — Santa Monica, California
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen

A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to well-differenti…

Sponsor: Crinetics Pharmaceuticals Inc.
NCT ID: NCT07087054
Sites in California:
  • Hoag Memorial Hospital Presbyterian — Newport Beach, California
View on ClinicalTrials.gov →
Phase 2, Phase 3 Recruiting Industry

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is …

Sponsor: AbbVie
NCT ID: NCT06109272
Sites in California:
  • City of Hope /ID# 261468 — Duarte, California
  • City of Hope at Orange County Lennar Foundation Cancer Center /ID# 261669 — Irvine, California
  • UC Irvine /ID# 255673 — Orange, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…

Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in California:
  • UC San Diego Moores Cancer Center — La Jolla, California
  • University of Southern California-Keck School of Medicine -1975 Zonal Ave — Los Angeles, California
  • University of Southern California — Newport Beach, California
  • University of California Irvine Medical Center — Orange, California
  • California Liver Research Institute — Pasadena, California
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

This phase II trial tests how well giving durvalumab with standard chemotherapy, gemcitabine and cisplatin, before surgery works in treating patients with high risk liver cancer (cholangiocarcinoma) that can be removed by surgery (resectab…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06050252
Sites in California:
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • Los Angeles General Medical Center — Los Angeles, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.

Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in California:
  • Helios Clinical Research — Cerritos, California
  • California Research Institute — Los Angeles, California
  • Sharp Memorial Hospital — San Diego, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

FOG-001 in Locally Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to determine if FOG-001 is safe and effective in participants with locally advanced or metastatic solid tumors.

Sponsor: Parabilis Medicines, Inc.
NCT ID: NCT05919264
Sites in California:
  • University of California, Los Angeles (UCLA) — Los Angeles, California
  • Stanford Cancer Institute, Stanford University — Palo Alto, California
  • University of California San Francisco, Helen Diller Family Comprehensive Cancer Center — San Francisco, California
  • Sarcoma Oncology Center — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (HCC) that is either…

Sponsor: Pfizer
NCT ID: NCT07227012
Sites in California:
  • Keck Hospital of USC — Los Angeles, California
  • Los Angeles General Medical Center — Los Angeles, California
  • USC/Norris Comprehensive Cancer Center / Investigational Drug Services — Los Angeles, California
  • USC/Norris Comprehensive Cancer Center — Los Angeles, California
  • Keck Medical Center of USC Pasadena — Pasadena, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.

Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in California:
  • Research Site 125 — Los Angeles, California
  • Research Site 133 — Los Angeles, California
  • Research Site 103 — Los Angeles, California
  • Research Site 128 — Santa Monica, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma

The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…

Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in California:
  • University of California San Diego — La Jolla, California
  • Norris Comprehensive Cancer Center — Los Angeles, California
  • University of California Irvine Medical Center — Orange, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…

Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital of Orange County — Orange, California
  • Lucile Packard Children's Hospital Stanford University — Palo Alto, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Network

Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma

This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…

Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital of Orange County — Orange, California
  • UCSF Medical Center-Mission Bay — San Francisco, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)

This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…

Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in California:
  • Los Angeles Cancer Network — Los Angeles, California
  • Valkyrie Clinical Trials — Los Angeles, California
  • Pih Health Hematology Medical Oncology — Whittier, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing…

Sponsor: Hoffmann-La Roche
NCT ID: NCT04524871
Sites in California:
  • UC Irvine Medical Center — Costa Mesa, California
  • City of Hope — Duarte, California
  • UC Irvine Medical Center — Orange, California
  • University of California San Diego Medical Center — San Diego, California
  • University of California San Francisco Cancer Center — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC

Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)

Sponsor: RayzeBio, Inc.
NCT ID: NCT06726161
Sites in California:
  • Research Facility — Orange, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

The purpose of this study is to assess the efficacy and safety of RP2 in combination with atezolizumab plus bevacizumab (Cohorts 1a and 1b) and RP2 monotherapy (Cohort 2) in the as second line treatment in patients with locally advanced un…

Sponsor: Replimune, Inc.
NCT ID: NCT05733598
Sites in California:
  • Beverly Hills Cancer Center — Beverly Hills, California
  • UC San Diego Moores Cancer Center — La Jolla, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)

Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in California:
  • Local Institution - 0137 — Duarte, California
  • Local Institution - 0070 — Los Angeles, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma

This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The s…

Sponsor: Iterion Therapeutics
NCT ID: NCT05797805
Sites in California:
  • City of Hope — Duarte, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours

This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GP…

Sponsor: AstraZeneca
NCT ID: NCT06795022
Sites in California:
  • Research Site — La Jolla, California
  • Research Site — Los Angeles, California
View on ClinicalTrials.gov →
Phase 2 Recruiting Academic/Other

Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma

This research study is studying an immunotherapy drug (pembrolizumab or KEYTRUDA) as a possible treatment for pediatric hepatocellular carcinoma or hepatocellular neoplasm not otherwise specified (HCN NOS).

Sponsor: Allison O'Neill, MD
NCT ID: NCT04134559
Sites in California:
  • University of California San Francisco — San Francisco, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting NIH

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other p…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06811116
Sites in California:
  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
  • UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Industry

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and ha…

Sponsor: Eureka Therapeutics Inc.
NCT ID: NCT04634357
Sites in California:
  • Children's Hospital Los Angeles — Los Angeles, California
  • Children's Hospital Orange County — Orange, California
  • UCSF Benioff Children's Hospitals — San Francisco, California
View on ClinicalTrials.gov →

Showing 25 of 76 trials with sites in California. See all liver cancer trials →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-07-07